Status: Recruiting
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
The objective of this study is to compare the safety and efficacy of RGN-259 to placebo for the treatment of Neurotrophic Keratopathy (NK)
Participants needed: 70
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: ReGenTree, LLCUpdated: Dec 23, 2025Locations: 36
Eligibility criteria
Be male or female of any race, at least 18 years of age; [+9]
Have any condition that, in the opinion of the Investigator, would interfere wit... [+20]